CLINICAL TRIALS PROFILE FOR MILNACIPRAN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Milnacipran Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00098124 ↗ | Study of Milnacipran for the Treatment of Fibromyalgia | Completed | Forest Laboratories | Phase 3 | 2004-11-01 | Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia. |
| NCT00225511 ↗ | Study Evaluating Effexor XR for Major Depression. | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2004-06-01 | Study Evaluating Effexor XR for Major Depression. |
| NCT00314249 ↗ | Study of Milnacipran for the Treatment of Fibromyalgia | Completed | Cypress Bioscience, Inc. | Phase 3 | 2006-04-01 | The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Milnacipran Hydrochloride
Condition Name
Clinical Trial Locations for Milnacipran Hydrochloride
Trials by Country
Clinical Trial Progress for Milnacipran Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Milnacipran Hydrochloride
Sponsor Name
